Vancouver, Canada

Jonathan Lehrer

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Veracyte Sd, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Lehrer. Retrieved from https://idiyas.com/inventor/jonathan-lehrer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jonathan Lehrer and His Work in Prostate Cancer Research.

Introduction

Jonathan Lehrer is an inventor associated with Vancouver, Canada. His patent work concerns the use of immune cell-specific gene expression to support prostate cancer prognosis and predict responsiveness to radiation therapy.

Latest Patents

Lehrer is named on 1 patent: “Use of Immune Cell-Specific Gene Expression for Prognosis of Prostate Cancer and Prediction of Responsiveness to Radiation Therapy.” The patent describes methods, systems, and kits for diagnosing prostate cancer, assessing its prognosis and progression, and identifying patients who may respond to radiation therapy.

Career Highlights

Lehrer is associated with Veracyte SD, Inc. His patent focuses on applying immune cell-specific gene expression to inform clinical assessment and treatment decisions for prostate cancer.

Collaborations

The provided information lists Felix Y. Feng and Elai Davicioni as some of Lehrer’s coworkers.

Conclusion

Jonathan Lehrer’s patent work centers on using gene-expression insights to improve prostate cancer prognosis and help identify patients who may benefit from radiation therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…